Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Research & Development: 2013-2024

Historic Research & Development for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $190.1 million.

  • ImmunityBio's Research & Development rose 1.56% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.9 million, marking a year-over-year decrease of 8.01%. This contributed to the annual value of $190.1 million for FY2024, which is 18.17% down from last year.
  • Per ImmunityBio's latest filing, its Research & Development stood at $190.1 million for FY2024, which was down 18.17% from $232.4 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Research & Development ranged from a high of $248.1 million in FY2022 and a low of $139.5 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $232.4 million (2023), whereas its average is $223.6 million.
  • Per our database at Business Quant, ImmunityBio's Research & Development soared by 40.46% in 2021 and then declined by 18.17% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Research & Development stood at $139.5 million in 2020, then soared by 40.46% to $196.0 million in 2021, then grew by 26.63% to $248.1 million in 2022, then declined by 6.36% to $232.4 million in 2023, then declined by 18.17% to $190.1 million in 2024.